DEFLAZACORT 6mg. IP

A synthetic corticosteroid acts as an anti-inflammatory/immunosuppressive agent that reduces inflammation and suppresses immunity to stop self-damage to the body by the immune system. (Anna Esposito, 2019) Has approximately the same anti-inflammatory potency as 5 mg prednisolone. (N Joshi, 2009) A derivative of prednisolone is characterized by high efficacy and good tolerability. (Luca Parente, 2017) Proven to be effective in the treatment of various rheumatological disorders. (Luca Parente, 2017) A promising therapeutic alternative in Duchenne muscular dystrophy, nephrotic syndrome, or renal transplantation. (Oscar Gonzalez-Perez, 2007) Recently approved by FDA for the treatment of Duchenne Muscular Dystrophy. (Anna Esposito, 2019) Produces less serious metabolic events due to low interference with carbohydrate and phosphocalcium metabolism as compared with previous-generation corticosteroids. (Anna Esposito, 2019) Effective as prednisone or methylprednisolone in rheumatoid arthritis population. (A Markham, 1995) Useful in the treatment of bronchial asthma and in the exacerbations of chronic obstructive pulmonary disease. (Luca Parente, 2017) Exerts a protective effect on bone erosion and joint damage in rheumatoid arthritis patients. (Luca Parente, 2017) Exerts 10–20 times higher anti-inflammatory effect than prednisolone and 40 times higher than hydrocortisone. (Luca Parente, 2017)